Bioprocessing Sponsored by MilliporeSigma
Zymeworks, Merck to develop multispecific antibodies
Merck has signed a research and licensing agreement to develop multispecific antibody therapeutic candidates using platforms from clinical-stage biopharmaceutical company Zymeworks.
AGC Biologics, Molecular Partners develop COVID-19 protein therapy
AGC Biologics has partnered with clinical-stage biotechnology company Molecular Partners to create a protein therapy against SARS-CoV-2, the virus that causes COVID-19.
Takeda, Twist partner on biologics discovery
Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies in Takeda's biologics pipeline.
$1.6B awarded to Novavax for COVID-19 vaccine
Novavax was awarded $1.6 billion by the U.S. government through Operation Warp Speed to deliver 100 million doses of a COVID-19 vaccine in 2021.
Xencor, Atreca to work on T cell-based cancer therapies
Biopharmaceutical company Xencor and biotechnology company Atreca have entered into a license agreement to research, develop, and commercialize T cell-engaging bispecific antibodies as potential cancer therapies.
CEPI expands Clover partnership on COVID-19 vaccine
The Coalition for Epidemic Prepardeness Innovations (CEPI) has expanded its partnership with Clover Biopharmaceuticals for the development and manufacture of Clover's COVID-19 S-Trimer vaccine candidate.
Horizon Discovery accelerates CRISPR gene editing workflows
Horizon Discovery Group has introduced a new stably expressing Cas9 cell line for knockout experiments and a dCas9-VPR cell line for gene activation experiments.
BARDA awards supply contract to Regeneron for COVID-19 cocktail
Regeneron Pharmaceuticals was awarded a $450 million contract to manufacture and supply its REGN-COV2 antibody cocktail that is currently in phase II/III clinical trials for the treatment of COVID-19 patients and phase III for the prevention of COVID-19.
Tessera introduces new genome engineering strategy
Flagship Pioneering, a life science venture capital firm, has introduced Tessera Therapeutics -- a new biotechnology company that will use its Gene Writing technology to cure diseases.
Regeneron begins COVID-19 antibody treatment phase III trial
Regeneron Pharmaceuticals has begun adaptive late-stage phase III clinical trials evaluating its antibody cocktail, REGN-COV2, for the treatment and prevention of COVID-19.
Conferences
BioProcess International Europe
July 13-17
Central European Time Zone (CET) Netherlands
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
General Discussion
Topic Replies / Views Last Update
https://academic.oup.com/ve/pages/coronavirus-evolution
by Michael
0 / 47 More than 3 days ago
by Michael
PopSci Hails Impossible Burger 2.0 as Most Important Engineering Innovation in 2019
by Mahesh Gupta
0 / 14 More than 3 days ago
by Mahesh Gupta
Engineered Bacteria Produces BeeFree Honey
by Mahesh Gupta
0 / 12 More than 3 days ago
by Mahesh Gupta
Consumers' Preference to Buy Unlabeled Produce Increases after Exposure to GMO-labeled Pro
by Mahesh Gupta
0 / 15 More than 3 days ago
by Mahesh Gupta
Super-precise new CRISPR tool could tackle a plethora of genetic diseases
by Mahesh Gupta
0 / 14 More than 3 days ago
by Mahesh Gupta
To see more posts from our community or to share a post of your own, go to our community's forum page.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter